Noor and Nord's Xultophy showed positive results

for patients with type 2 diabetes with inadequate oral treatment control, Novo Nordisk's Xultophy (degludec/liraglutide) significantly delayed the strengthening of treatment time compared to insulin glablin U100.
The results of the DUAL VIII trial were presented at the 79th Scientific Meeting of the American Diabetes Association (ADA) in San Francisco and published in the journal
Lancet Diabetes and Endocrinology
.
The combination of insulin degludec and liraglutide helps patients achieve blood sugar goals and is safe.
Data show that over 104 weeks, about 63 percent of study participants who received Xultophy did not require additional treatment, while about 34 percent of patients treated with insulin glycelin U100. To reflect the objectives of clinical practice, participants were tracked on average once every three months and met treatment enhancement standards when HbA1c measurements were ≥7% for two consecutive periods.
After the same number of weeks, Xultophy's arm required significantly fewer insulin units (37 to 52), significantly lower weight gain (1.7 kg vs 3.4 kg), and a 56% reduction in severe or hypoglycemia diagnosis.
"In the trial, they were not just looking for clinical markers such as HbA1c or weight-influenced, but were solving a critical clinical problem: how long each treatment would take to help patients achieve and maintain effective blood sugar control once activated," said Vanita Arida, clinical director of clinical research on Brigham Diabetes and lead trial researcher. She continued,
The study shows us that in patients with inadequate oral treatment control, it is possible to double the time it takes to start using IDegLira compared to insulin glycerion U100 therapy. In clinical practice, this becomes relevant because the longer patients can maintain good control, the less exposure to high blood sugar and the less escalation or change in treatment. " (Compiled by this web)